Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 May;34(2):357-64.
doi: 10.1016/j.iac.2014.01.013. Epub 2014 Mar 13.

Eosinophilia in mast cell disease

Anna Kovalszki  1 , Peter F Weller  2
Affiliations
Review

Eosinophilia in mast cell disease

Anna Kovalszki et al. Immunol Allergy Clin North Am. 2014 May.

Abstract

Eosinophils and mast cells coexist in clonal and nonclonal disorders. The interplay between these cells is complex and not fully understood. Discussed are both allergic/nonclonal disorders in which both cell types are increased in number are likely to play a role in pathogenesis and clonal disorders in which both cell types are affected and play key roles in pathogenesis. Finally, some treatment options, keeping both disorders in mind, are discussed. Future directions in thinking about these disorders are also briefly explored.

Keywords: Chronic eosinophilic leukemia (CEL); Eosinophilia; FIP1L1-PDGFRA fusion; Hypereosinophilic syndrome; Imatinib; Systemic mastocytosis; Tryptase.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Workup of uncharacterized eosinophilia. 1. World Health Organization criteria for systemic mastocytosis (see Box 1). 2. Tyrosine kinase mutations in chronic eosinophilic leukemia. Including but not limited to FIP1L1-PDGFRA fusion, fusion of PDGFRA with other partner genes, fusions involving PDGFRB. 3. Formerly known as Churg-Strauss syndrome.
Fig. 2
Fig. 2
Bone marrow biopsy and aspirate in a patient with chronic eosinophilic leukemia carrying the FIP1L1-PDGFRA rearrangement. Increased numbers of hypogranulated neoplastic eosinophils are observed in the aspirate (A, B) (Wright-Giemsa, original magnification ×100). The infiltrate predominantly consists of eosinophils in a background of fibrosis in the biopsy (C, D) (Hematoxylin and Eosin, original magnification ×400) as opposed to mastocytosis whereby the predominant infiltrate is that of mast cells. (Courtesy of German A. Pihan, MD, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.)
Fig. 3
Fig. 3
(A) Bone marrow biopsy in systemic mastocytosis, intermediate magnification (Hematoxylin and Eosin, 100×) featuring atypical, spindle-shaped mast cells and intermingled eosinophils surrounding a lymphoid aggregate. (B) Bone marrow biopsy in systemic mastocytosis, high magnification (Hematoxylin and Eosin, 400×) showing atypical, spindle-shaped mast cells (M) with numerous intermingled eosinophils (E). (Courtesy of Charles W. Ross, MD, University of Michigan, Ann Arbor, MI.)
See this image and copyright information in PMC

References

    1. Metcalfe DD. Mastocytosis. In: Adkinson NF Jr, editor. Middleton's allergy principles and practice. 8th edition Vol. 2. Saunders Elsevier; Philadelphia: 2014. pp. 1224–36.
    1. Gotlib J, Akin C. Mast cells and eosinophils in mastocytosis, chronic eosinophilic leukemia, and non-clonal disorders. Semin Hematol. 2012;49(2):128–37. - PubMed
    1. Klion AD, Weller PF. Eosinophilia and eosinophil related disorders. In: Adkinson NF Jr, editor. Middleton's allergy principles and practice. 8th edition Vol. 2. Saunders Elsevier; Philadelphia: 2014. pp. 1205–23.
    1. Otani IM, Anilkumar AA, Newbury RO, et al. Anti-IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis. J Allergy Clin Immunol. 2013;131(6):1576–82. - PMC - PubMed
    1. Kovalszki A, Sheikh J, Weller PF. Eosinophils and eosinophilia. In: Rich RR, editor. Clinical immunology principles and practice. 4th edition Vol. 1. Elsevier Saunders; Philadelphia: 2013. pp. 298–309.

MeSH terms